Why GlaxoSmithKline plc And Shire plc Are Dividend And Growth Buys

This Fool thinks it’s time to invest in GlaxoSmithKline plc (LON: GSK) and Shire plc (LON: SHP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) would be my pick of the pharmaceutical companies to invest in at the moment. While GSK is a dividend investment, Shire is a growth play. Let’s look at each company in turn.

GlaxoSmithKline

Glaxo is one of the world’s largest pharmaceutical companies, with strengths in asthma, cancer, diabetes and digestive diseases. It has been a firm renowned as having one of the strongest drugs pipelines in the pharma industry.

Yet in the last few years it has not quite lived up to expectations. Last year the company was damaged in one of its fastest growing markets by the bribery scandal in China. Sales of several blockbuster drugs have fallen as their patents have expired, while newly launched drugs, although selling well, have not matched the big sellers of yesteryear.

Yet this remains one of the most innovative healthcare businesses in the world. I think what GlaxoSmithKline and the rest of the pharmaceutical industry is learning, just like the TV industry learnt before it, and supermarket retail is learning now, is how to adapt to the world of the long tail.

You see, in the past many drugs were so popular they sold more than the rest of the market put together. You can think of Zantac and Losec as the Jewel in the Crown and Upstairs Downstairs of pharma. These drugs sold in their millions, and made drugs companies billions.

But today if you want to buy a drug because you are suffering from a bit of heartburn, alongside Zantac and Losec you have Nexium, Dexilant, Reglan and perhaps a dozen other branded drugs. The days when one drug grabbed the bulk of the market are gone.

That’s why I think that traditional pharmaceutical companies such as GSK are unlikely to grow quickly. But they are still highly profitable, and generate prodigious amounts of cash. That’s why they are the ideal dividend shares. Glaxo is currently on a 2015 P/E ratio of 16.4 with a dividend yield of 5.2%. That’s a high yield, which is well covered by profits. I view this as a strong dividend buy.

Shire

One of the tragedies of the past was that if you suffered from a rare disease, the likelihood was that there would be no treatment. These days, things are different. Shire is a business built upon the idea that you produce targeted treatments to a wide variety of diseases by use of the latest science and biotechnology.

Shire, instead of being a pharmaceutical titan, is really a network of smaller companies, each designed to tackle a particular ailment. You see, myriad rare diseases now have myriad treatments. And the world of the long tail is about a lot more than spaghetti sauce or TV programmes.

Who would have thought that such an apparently disparate business would be so successful and so profitable? The earnings per share progression shows how quickly this company is growing:

2011: 97p

2012: 86p

2013: 148p

2014: 229p

2015: 245p

A 2014 P/E ratio of 22.0, falling to 20.6 in 2015 sounds expensive, but I think this is a clear growth buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close up of manual worker's equipment at construction site without people.
Investing Articles

With H1 profits back on track, is this FTSE 250 housebuilder ready to bounce back?

Operating profits are down 22% at Vistry. But as cost issues give way to government support, could the FTSE 250…

Read more »

Investing Articles

2 fantastic UK growth stocks to consider for a Stocks and Shares ISA

Looking for opportunities for a Stocks and Shares ISA portfolio? Our writer shares two ideas from the London Stock Exchange.

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Investors could target £8,840 of annual dividend income from 5,851 shares in this FTSE 250 high-yield star!

Shares in this FTSE 250 stock generate a much higher dividend yield than the index average and can produce potentially…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

HSBC’s share price has dipped 5% to just over £9, so should I buy more right now?

HSBC’s share price has dipped in recently, but this could signal a bargain to be had. I ran the key…

Read more »

many happy international football fans watching tv
Investing Articles

Is this FTSE 250 stock gearing up to more than double its market cap by October?

Our writer considers the implications of a recent stock market announcement for the share price of this FTSE 250 retailer.…

Read more »

Inflation in newspapers
Investing Articles

3 overlooked UK shares growing dividends faster than inflation

Mark Hartley highlights three lesser-known UK shares offering inflation-beating dividends, while noting key risks investors should watch.

Read more »

Belfast City Sunset with colorful twilight over Lagan Weir Pedestrian and Cycle Bridge spanning over the Lagan River in downtown Belfast
Investing Articles

My 3 ‘secret’ rules I always follow when hunting passive income stocks

Mark Hartley reveals three perhaps not-so-secret tips he uses to ensure his passive income strategy doesn't come back to bite…

Read more »

Man riding the bus alone
Investing Articles

Is there a good reason to consider Greggs shares?

Greggs' shares have been in a state of decline over the past 12 months. However, Dr James Fox remains concerned…

Read more »